glp-1 kidney disease news Receptor Agonists and Diabetic Disease: A Call of Attention to Nephrologists GLP-1s lower BMI, preserve kidney
Description
An analysis of MACE by SGLT2i use showed no evidence of heterogeneity in the effects of oral semaglutide with evidence for significant benefit in subjects taking SGLT2i
No brand names or devices are discussed publicly to remain compliant with Singapores medical advertising regulations
Data were normalized to maximum concentrations of GLP-1 or GIP (100%) and no ligand (0%) and analyzed by nonlinear regression (sigmoidal concentration-response) and plotted using GraphPad Prism 7 software
Smith and Dr
[DOI] [PMC free article] [PubMed] [Google Scholar] 54.Matsukawa A., Takeda K., Kudo S., Maeda T., Kagayama M., Akira S
Like Ozempic, it can help lower the risk of major adverse cardiovascular events (MACE) in adults who also have heart disease
